Andrew Cuthbertson
Director/Board Member at ZENYTH THERAPEUTICS LIMITED
Net worth: 13 M $ as of 30/03/2024
Profile
Presently, Andrew Cuthbertson occupies the position of Chief Scientific Officer & Executive Director at CSL Ltd. and Chief Scientific Officer of CSL Behring LLC (a subsidiary of CSL Ltd.). He is also on the board of CSL Innovation Pty Ltd., Centre for Eye Research Australia and Grattan Institute and Council Member at the University of Melbourne. Andrew Cuthbertson previously occupied the position of Senior Scientist at Genentech, Inc.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
CSL LIMITED
0.01% | 15/02/2024 | 70,391 ( 0.01% ) | 13 M $ | 30/03/2024 |
Andrew Cuthbertson active positions
| Companies | Position | Start |
|---|---|---|
| ZENYTH THERAPEUTICS LIMITED | Director/Board Member | - |
| CSL LIMITED | Director/Board Member | 16/10/2018 |
CSL Behring LLC
 CSL Behring LLC BiotechnologyHealth Technology CSL Behring LLC researches, develops, manufactures, and markets biotherapies that are used to treat serious and rare conditions. It offers protein-based therapies in the areas of Bleeding Disorders, Fluid Replacement, Hereditary Angioedema, Immunoglobulin, Pulmonary, and Wound Healing Therapies. The company was founded in 2004 and is headquartered in King of Prussia, PA. | Director/Board Member | 31/12/2017 |
University of Melbourne
 University of Melbourne Other Consumer ServicesConsumer Services The University of Melbourne, founded in 1853, is a world-renowned institution located in Parkville, Australia. The university is a leader in education, teaching, and research, offering a wide range of coursework and research programs. | Corporate Officer/Principal | 31/12/2015 |
| Centre for Eye Research Australia | Director/Board Member | 28/02/2017 |
Grattan Institute
 Grattan Institute Miscellaneous Commercial ServicesCommercial Services Grattan Institute develops public policy programs. The private company is based in Carlton, Australia. The CEO of the Australian company is John Daley. | Director/Board Member | 31/12/2018 |
Former positions of Andrew Cuthbertson
| Companies | Position | End |
|---|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | 31/12/1996 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| CSL LIMITED | Health Technology |
| Private companies | 5 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
CSL Innovation Pty Ltd.
 CSL Innovation Pty Ltd. Pharmaceuticals: MajorHealth Technology CSL Innovation Pty Ltd. develops pharmaceutical products. The firm also develops human antibody inhibitors of the granulocyte-macrophage colony stimulating factor receptor alpha subunit, GM-CSFRa, for potential therapeutic use in inflammatory diseases. The company was founded in 1986 and is headquartered in Richmond, Australia. | Health Technology |
CSL Behring LLC
CSL Behring LLC BiotechnologyHealth Technology CSL Behring LLC researches, develops, manufactures, and markets biotherapies that are used to treat serious and rare conditions. It offers protein-based therapies in the areas of Bleeding Disorders, Fluid Replacement, Hereditary Angioedema, Immunoglobulin, Pulmonary, and Wound Healing Therapies. The company was founded in 2004 and is headquartered in King of Prussia, PA. | Health Technology |
| Centre for Eye Research Australia | Government |
Grattan Institute
Grattan Institute Miscellaneous Commercial ServicesCommercial Services Grattan Institute develops public policy programs. The private company is based in Carlton, Australia. The CEO of the Australian company is John Daley. | Commercial Services |
- Stock Market
- Insiders
- Andrew Cuthbertson
